Drug Discovery World

JANUARY 12, 2024

Nipah virus is mostly found in South-East Asia that can be fatal in up to 75% of cases. Despite the first outbreaks occurring 25 years ago in Malaysia and Singapore, there are currently no approved vaccines or treatments. This trial is a step forward in efforts to build a suite of tools to protect against this killer virus.

Virus 130

Virus Vaccine Trials Clinical Trials 130

Drug Discovery World

AUGUST 15, 2023

But targeting these proteins has limitations, as viruses can quickly evolve, changing the properties of the proteins and making treatments less effective. Most viruses that cause disease are encapsulated in membranes made of lipids, and antimicrobial peptides work by disrupting or even bursting these membranes.

Virus 130

Virus Vaccine Treatment Research 130

Drug Discovery World

JANUARY 29, 2024

Researchers have found a virus that kills dormant bacteria, a discovery that could help to combat infections that can’t be treated with antibiotics. When tested in cell culture dishes, the virus was able to kill 99% of all dormant bacteria but left 1% alive. They have named their new phage Paride.

Virus 130

Virus Hospitals Treatment Research 130

Drug Discovery World

JUNE 28, 2024

A new Phase II trial, REGENERATE-PD, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic factor (GDNF) gene therapy for the treatment of moderate-stage Parkinson’s disease. The trial will include an estimated 87 subjects with study sites located in the US, UK and Europe.

Therapies 147

Therapies Disease Medical Schools Trials 147

Drug Discovery World

MARCH 17, 2023

The Scottish Medicines Consortium (SMC) has become the first UK health authority to permit routine NHS use of Gilead Sciences’ Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection. However, to date, there have been severely limited treatment options for those affected.

Virus 130

Virus Regulations Licensing Licensing 130

Drug Discovery World

JANUARY 11, 2024

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. Patients affected by the disease are found to also experience an imbalance of glutathione regulation, which is important for liver detoxification.

Disease 147

Disease Research RNA Therapies 147

Drug Discovery World

DECEMBER 22, 2022

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV. . The post AI identifies drug candidates for respiratory syncytial virus appeared first on Drug Discovery World (DDW).

Virus 130

Virus Clinical Trials Drugs Hospitals 130

Drug Discovery World

AUGUST 23, 2022

A Phase I/II clinical trial targeting a treatment for Huntington’s Disease (HD) using a gene therapy has been given the clearance to go ahead in France. . There are currently no approved disease modifying therapies for Huntington’s Disease. In 2019, BV-101 was granted orphan drug designation in the European Union. .

Therapies 246

Therapies Disease Trials Clinical Trials 246

Drug Discovery World

FEBRUARY 1, 2024

These deposits can cause progressive damage to the brain and other areas of the body. Disease symptomatology is characterised by chronic diarrhea during infancy and cataracts in late childhood. At present there is no cure for CTX, only treatment to slow disease progression. Vivet Therapeutics has received €4.9

Therapies 130

Therapies Treatment Disease Virus 130

Drug Discovery World

DECEMBER 6, 2022

CAR-T therapy can be used to eliminate unwanted cells that cause autoimmunity, according to the results of a new study in mice with an autoimmune disease similar to multiple sclerosis (MS). . I believe that this is a fully treatable disease, and CAR-T cells may be the way toward much better therapeutics.” .

Disease 214

Disease Therapies Virus Treatment 214

Chemical Biology and Drug Design

APRIL 18, 2023

The severity of chagas disease remains a major concern in endemic areas and an emerging public health hazard in nonendemic countries. Abstract Twenty different infectious disorders induced by bacteria, viruses, and parasites are categorized as neglected tropical diseases (NTDs) by WHO.

Disease 100

Disease Treatment Virus Therapies 100

Drug Discovery World

NOVEMBER 9, 2022

Poolbeg Pharma and partner OneThree Biotech have discovered novel drug targets for the treatment of respiratory syncytial virus (RSV) using an artificial intelligence (AI) programme. . The AI model allows for the complex disease signature underlying each drug target to be considered during drug selection. .

Disease 130

Disease Small Molecule Virus Trials 130

Drug Discovery World

MAY 6, 2024

It was also found that B cells which were consistently present in patients’ treatment had recognised cancer and had changed their genetic sequence to become more effective at identifying cancer. B cells are similar to T cell in that they work as part of the immune system to help fight infections as well as cancer.

Treatment 130

Treatment Research Immune Response Virus 130

Drug Discovery World

JULY 14, 2022

Pharmaceutical company SIGA Technologies has announced that its oral therapy tecovirimat has been approved in the UK for the treatment of smallpox, monkeypox, cowpox. . The therapy has also been approved for the treatment of complications following vaccination against smallpox in adults and children with a body weight of at least 13kg. .

Treatment 130

Treatment Pharmaceutical Companies Vaccine Virus 130

Drug Discovery World

APRIL 13, 2023

A National Institutes of Health (NIH) clinical trial was stopped early because a daily statin medication was found to reduce the increased risk of cardiovascular disease among people living with HIV. Advances in HIV treatment have drastically reduced AIDS-related complications and deaths.

Disease 130

Disease Clinical Trials Trials Virus 130

Drug Discovery World

OCTOBER 24, 2022

A scientist at Oregon State University has demonstrated in a mouse model that it’s possible to prompt the production of a protein that can block multiple variants of the SARS-CoV-2 virus from entering cells and causing respiratory disease. . This prevents the virus from latching onto cells in the host’s airway. .

Treatment 100

Treatment RNA Protein Production Virus 100

ProRelix Research

SEPTEMBER 7, 2023

Autoimmune disorders comprise several diseases in which the immune system mistakenly attacks and destroys the body’s own healthy cells instead of destroying bacteria and viruses to keep the body healthy. […] The post Autoimmune disorders and current developments of novel treatments under clinical trials appeared first on ProRelix Research.

Clinical Trials 105

Clinical Trials Trials Treatment Virus 105

Drug Discovery World

JULY 12, 2024

Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia gravis, non-small cell lung cancer, Marburg virus, and Parkinson’s disease. for disease-modifying Parkinson’s treatment Mission Therapeutics has been awarded $5.2

Clinical Trials 130

Clinical Trials Virus Trials Vaccine 130

Drug Discovery World

JUNE 28, 2024

This week has seen some exciting advances in neuroscience drug discovery, including Phase II clinical trials for two potentially game-changing treatments, a synapse-regenerating drug for Alzheimer’s and a gene therapy for Parkinson’s, as well as the launch of DDW’s latest In Focus report.

Clinical Trials 130

Clinical Trials Drugs Trials Virus 130

Drug Discovery World

AUGUST 24, 2022

A new study investigating a potential treatment for people who have been diagnosed with monkeypox has been launched by the same team who helped develop Covid-19 treatments. . The trial will see participants receive either a 14-day course of 600 mg tecovirimat twice daily or a matched placebo treatment.

Research 246

Research Clinical Trials Virus Trials 246

Drug Discovery World

MAY 24, 2024

The top stories: Partners explore precision medicine approach to heart disease PlaqueTec and the Welch research group at the Babraham Institute have announced the completion of their collaboration to evaluate lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec.

Virus 130

Virus Drugs Vaccine Disease 130

Drug Discovery World

OCTOBER 9, 2023

Despite the size of the market and the global impact, there are currently no effective treatments. In short, the virus crashes the CPU, and the whole system slows down significantly. DS: As new variants begin circulating, what impact could this finding have on our understanding and the potential treatment of long Covid?

Drug Development 147

Drug Development Clinical Trials Virus Drugs 147

Drug Discovery World

JULY 12, 2024

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Asklepios BioPharmaceutical’s (AskBio) AB-1005 which is being developed for moderate Parkinson’s disease. AB-1005 is an investigational adeno-associated virus 2 glial cell line-derived neurotrophic factor (AAV2-GDNF) neurorestorative gene therapy.

Therapies 147

Therapies Clinical Trials FDA Clinical Development 147

Drug Discovery World

OCTOBER 21, 2022

Amid continued concern about antibiotic resistance, the headline news this week was the discovery of a new antibiotic that could be effective against some of the most treatment-resistant pathogens. . A research team from Boston University has caused controversy for work involving the creation of a hybrid SARS-CoV-2 virus. .

Small Molecule 130

Small Molecule Virus Drugs Clinical Trials 130

Drug Discovery World

SEPTEMBER 12, 2024

Alfacyte is being developed for the treatment of upper respiratory tract infections and as a broad-spectrum antiviral. It has demonstrated activity against multiple viruses and is currently being developed for respiratory syncytial virus (RSV), with further proof-of-concept studies intended in other indications.

Virus 147

Virus Engineering Clinical Development Drug Development 147

Drug Discovery World

MAY 13, 2024

MA: Regarding vaccine development specifically, and the role my team plays in the development of cryogenic electron microscopy (cryo-EM) technology, we see the study and dissemination of virus structures, and the proteins that comprise them, as vital to vaccine design. MA: Respiratory viruses represent a diverse group of pathogens.

Vaccine 147

Vaccine Virus Small Molecule Disease 147

Drug Discovery World

JULY 19, 2022

An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection. . The clinical trial has been launched by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate an investigational vaccine to prevent infection with Nipah virus. Official comments .

Clinical Trials 130

Clinical Trials Trials Virus Vaccine 130

Drug Discovery World

APRIL 30, 2024

During 2023, 16 antibody therapeutics were granted approvals in the US or EU, either for the first time or for a new indication, covering uses as diverse as cancer, Alzheimer’s disease, diabetes and respiratory syncytial virus.

Clinical Research 130

Clinical Research Drugs Engineering Virus 130

Drug Discovery World

AUGUST 18, 2023

My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted in the future.

Small Molecule 130

Small Molecule Virus Drugs Clinical Research 130

Drug Discovery World

SEPTEMBER 11, 2024

The trial also tested the safety profile of the treatment. In collaboration with her husband Sanford Boye, Shannon Boye’s lab developed the virus-based transport system that is essential for delivering functioning copies of the GUCY2D gene into the correct cells in the eyes.

Therapies 147

Therapies Trials Clinical Trials Laboratories 147

Drug Discovery World

JUNE 29, 2023

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, has announced a breakthrough in its influenza AI Programme with CytoReason. Poolbeg has been working with CytoReason since March 2022.

Drugs 245

Drugs Virus Disease Trials 245

Codon

AUGUST 26, 2024

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus.

RNA 93

RNA Virus DNA Vaccine 93

Broad Institute

JUNE 18, 2024

Simple test for flu could improve diagnosis and surveillance By Allessandra DiCorato June 18, 2024 Breadcrumb Home Simple test for flu could improve diagnosis and surveillance A low-cost CRISPR-based paper strip test distinguishes between influenza types and can be reprogrammed to recognize different viruses including the H5N1 bird flu virus.

Virus 144

Virus RNA Medical Schools Laboratories 144

Drug Discovery World

JULY 24, 2023

The following novel medicines and biosimilars each received a positive opinion: Abrysvo (bivalent, recombinant) , a vaccine to protect small infants and older people against lower respiratory tract disease caused by respiratory syncytial virus (RSV). Inaqovi (decitabine/cedazuridine) for the treatment of acute myeloid leukaemia.

Biosimilars 130

Biosimilars Virus Treatment Marketing 130

Drug Discovery World

NOVEMBER 3, 2022

Research led by The University of Queensland has found that Covid-19 activates the same inflammatory response in the brain as Parkinson’s disease. . The discovery identified a potential future risk for neurodegenerative conditions in people who have had Covid-19, but also a possible treatment. . The treatment.

Virus 130

Virus Clinical Trials Disease Treatment 130

The Pharma Data

MAY 15, 2023

CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV) Gilead Sciences, Inc. Bulevirtide was initially granted conditional marketing authorisation in July 2020 to provide people living with HDV urgent access to treatment. In the U.S.

Virus 40

Virus Marketing Treatment Medical Schools 40

The Pharma Data

APRIL 27, 2023

There are no RSV vaccines or specific treatments currently available for older adults. 1 If approved, GSK’s candidate has the potential to be the first vaccine available to help protect older adults from RSV disease. GSK’s marketing authorisation application has been reviewed under accelerated assessment.

Virus 40

Virus Vaccine Trials Clinical Trials 40